Search results
Results from the WOW.Com Content Network
The Journal of the National Comprehensive Cancer Network, established in 2003, is a monthly peer-reviewed medical journal of oncology and the official journal of the National Comprehensive Cancer Network (NCCN). It is published by Harborside Press and the editor-in-chief is Margaret Tempero (UCSF Helen Diller Family Comprehensive Cancer Center ...
"The National Comprehensive Cancer Network (NCCN)". J Med Libr Assoc. 92 (3): 382– 3. PMC 442186. "New developments from National Comprehensive Cancer Network (NCCN) outlined recently" Physician Law Weekly August 1, 2007 "New Guidelines Updates from National Comprehensive Cancer Network"Cancerwatch Online (March 2004) 13(3)
3D medical illustration depicting the TNM stages in breast cancer. Cancer staging can be divided into a clinical stage and a pathologic stage. In the TNM (Tumor, Node, Metastasis) system, clinical stage and pathologic stage are denoted by a small "c" or "p" before the stage (e.g., cT3N1M0 or pT2N0).
Cervical cancer is a type of gynecological cancer that begins from cells lining the cervix, the lower part of the uterus. [14] Cervical cancer begins when the cells that line the cervix become abnormal and grow in a pattern that is atypical for non-cancerous cells. [14] Cervical cancer is typically first identified with an abnormal pap smear. [14]
Cervical cancer is a cancer arising from the cervix or in any layer of the wall of the cervix. [2] It is due to the abnormal growth of cells that can invade or spread to other parts of the body. [12] Early on, typically no symptoms are seen. [2] Later symptoms may include abnormal vaginal bleeding, pelvic pain or pain during sexual intercourse. [2]
Cervical cancer screening is a medical screening test designed to identify risk of cervical cancer. Cervical screening may involve looking for viral DNA, and/or to identify abnormal, potentially precancerous cells within the cervix as well as cells that have progressed to early stages of cervical cancer .
The Bethesda system (TBS), officially called The Bethesda System for Reporting Cervical Cytology, is a system for reporting cervical or vaginal cytologic diagnoses, [1] used for reporting Pap smear results. It was introduced in 1988 [2] and revised in 1991, [3] 2001, [1] [4] [5] and 2014. [6]
The cause of CIN is chronic infection of the cervix with HPV, especially infection with high-risk HPV types 16 or 18. It is thought that the high-risk HPV infections have the ability to inactivate tumor suppressor genes such as the p53 gene and the RB gene, thus allowing the infected cells to grow unchecked and accumulate successive mutations, eventually leading to cancer.